Mumbai, Nov. 9 -- The company has launched Desloratadine Tablets USP, 5 mg, in 100-count and 500-count packs through its wholly owned US subsidiary, Morepen Bio Inc. Desloratadine is an active pharmaceutical ingredient (API) that Morepen has been supplying to the US market for several years.

The launch marks the company's entry into finished-dosage medicines and US distribution, extending its presence beyond API supplies. The move is part of its broader strategy to expand its pharmaceutical research and development (R&D), contract development and manufacturing (CDMO) and formulations businesses.

Separately, Morepen has submitted its first Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA) for Sitaglipti...